Clarus Therapeutics, Inc.

Sonus Pharmaceuticals, Inc.

Louisiana State University and Agricultural & Mechanical College

Abbott Laboratories Corporation

Amcol International Corporation

Soligenix, Inc.

Tolmar, Inc.

Theravasc Inc.

Panayiotis P Constantinides

Robert E Dudley

Karel J Lambert

Steven C Quay

Alexander K Tustian

Christopher Kevil

Anthony J Giordano

Douglas R Flanagan

Jerald W Darlington, Jr

Likan Liang

Dilip Kaul

Laman A Al-Razzak

John M Lipari

Nagesh Palepu

Dean R Kessler

Bashar Y Abdullah

Lisa L McChesney-Harris

Eun-Hyun Jang

Wael Salameh

Andrew M Nienstedt

Robert Dudley

Anthony Giordano

A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Pharmaceutical formulations of nitrite and uses thereof

Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.

Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents

The invention relates to compositions and methods for drug delivery suitable for promoting the transmucosal absorption of drugs, especially drugs with poor intrinsic bioavailability, such as peptides, proteins, vaccines, and nucleic acids. The delivery system of this invention preferably comprises fatty acid esters and their hydrophilic derivatives that associate with water and other polar solvents to form reverse micelles that are physically stabilized in the presence of gastrointestinal fluid, water, and other hydrophilic solvents. Such stable reverse micelles are formed by suitable mixtures of polymeric or non-polymeric compounds with amphiphiles. Micelles made using these methods undergo phase transformation more slowly resulting in delayed drug release profiles and sustained absorption. When administered as a pharmaceutical to mucosal surfaces following oral ingestion or intranasal administration, therapeutic molecules principally solubilized in the aqueous phase are protected from digestion by mucosal enzymes and other mucosal degradative processes and are taken up by absorptive cell mechanisms and reach appropriate body compartments. The reverse micelle compositions may comprise mono-, di-glycerides and/or their transesterified products containing C6-C12 fatty acids chains, wherein the transester groups consist of hydrophilic moieties.

Stabilized reverse micelle compositions and uses thereof

Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal.

Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal

Growing community of inventors

Gurnee, IL, United States of America

Panayiotis P Constantinides